Astellas Pharma Gmbh

Forestry and Forest Products Research Institute

Arialys Therapeutics, Inc.

Satoshi Kubo

Daisuke Yamajuku

Takashi Honda

Akifumi Morinaka

Shinji Soga

Mutsumi Seki

Atsuo Kanno

Harumi Honma

Tatsuhiko Yamada

Masanobu Nojiri

Takuya Kito

Masashi Maeda

Takuma Mihara

Yasumitsu Uraki

The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.

Anti-human NR1 antibody derivative

Described herein are novel anti-human Ig&#x3b2; antibodies, as well as methods for making the antibodies and using the antibodies to treat or prevent autoimmune disease.

Anti-human Ig&#x3b2; antibody

[Problem] Provided is an anti-human Ig&#x3b2; antibody which crosslinks BCR and Fc&#x3b3;RIIb and has an immunosuppressive function more enhanced than that of an antibody in the prior art. [Means for Solution] An anti-human Ig&#x3b2; antibody comprising a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 65 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of amino acid numbers 98 to 108 of SEQ ID NO: 2, a light chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 38 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of amino acid numbers 54 to 60 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of amino acid numbers 93 to 101 of SEQ ID NO: 4, and a heavy chain constant region which is a human Ig&#x3b3;1 constant region having amino acid mutations of S239D, H268D, and L328W.

The invention relates to an enzyme stabilizer comprising a lignin derivative produced by reaction between lignin and a hydrophilic compound, and to a method of saccharifying lignocellulosic biomass which employs the enzyme stabilizer. According to the invention it is possible to accomplish effective saccharification of cellulosic biomass with saccharifying enzymes, by enhancing saccharifying enzyme activity and preventing nonspecific adsorption of saccharifying enzyme onto substrate.

Lignin-based enzyme stabilizer

Growing community of inventors

Tokyo, Japan

Satoshi Kubo